Forimtamig, a novel GPRC5D-targeting T-cell bispecific antibody with a 2+1 format, for the treatment of multiple myeloma
Blood · 2025
DOI: 10.1182/blood.2024025987 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Blood, 2025. Verfasst von Jan Eckmann und 45 weiteren Autor:innen. Beteiligte Einrichtung: Discovery Oncology, Roche Pharma Research and Early Development, Roche Innovation Center, Munich, Germany. Hauptthemen laut MEDLINE: Antibodies, Bispecific, Multiple Myeloma, Receptors, G-Protein-Coupled, T-Lymphocytes. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Despite several approved therapies, multiple myeloma (MM) remains an incurable disease with high unmet medical need. “Off-the-shelf” T-cell bispecific antibodies (TCBs) targeting B-cell maturation antigen (BCMA) and G protein–coupled receptor class C group 5 member D (GPRC5D) have demonstrated high objective response rates in heavily pretreated patients with MM; however, primary resistance, short duration of response, and relapse driven by antigen shift frequently occur. Although GPRC5D represents the most selective target in MM, recent findings indicate antigen loss occurs more frequently than with BCMA. Thus, anti-GPRC5D immunotherapies must hit hard during a short period of time. Here, we characterize forimtamig, a novel GPRC5D-targeting TCB with 2+1 format. Bivalent binding of forimtamig to GPRC5D confers higher affinity than classical 1+1 TCB formats correlating with formation of more stable immunological synapses and higher potency in tumor cell killing and T-cell activation. Using an orthotopic mouse model of MM, forimtamig recruited T effector cells to the bone marrow and induced rapid tumor killing even after the introduction of step-up dosing to mitigate cytokine release. Combination of forimtamig with standard-of-care agents including anti-CD38 antibodies, immunomodulatory drugs, and proteasome inhibitors improved depth and duration of response. The combination of forimtamig with novel therapeutic agents including BCMA TCB and cereblon E3 ligase modulatory drugs was potent and prevented occurrence of GPRC5D -negative tumor relapse. Forimtamig is currently being evaluated in phase 1 clinical trials in patients with relapsed and refractory MM for monotherapy and in combination treatments. This trial was registered at www.ClinicalTrials.gov as #NCT04557150.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Discovery Oncology, Roche Pharma Research and Early Development, Roche Innovation Center, Munich, Germany.
- Discovery Oncology, Roche Pharma Research and Early Development, Roche Innovation Center, Zurich, Switzerland.
- Clínica Universidad de Navarra, Centro de Investigación Médica Aplicada, University of Navarra, Pamplona, Spain.
- Discovery Oncology, Roche Pharma Research and Early Development, Roche Innovation Center, Basel, Switzerland.
- Cancer Research Center of Toulouse, INSERM, Centre National de la Recherche Scientifique, Université Toulouse III-Paul Sabatier, Toulouse, France.
- Institute of Experimental Immunology, University of Zurich, Zurich, Switzerland.
ORCID-Profile: Jan Eckmann, Laura Blanco, Iva Lelios, Sahar Kassem, Alexander Bujotzek, Jan Attig, Floriana Cremasco, Felix Bormann, Thomas Kraft, Carina Hage, Gordon Heidkamp, Thomas Pöschinger, Maud Mayoux, Felipe Prosper, Ludovic Martinet, Stéphane Leclair, Wei Xu, Bruno Paiva, Christian Klein
Zitieren
APA
Eckmann, J., Fauti, T., Biehl, M., Zabaleta, A., Blanco, L., Lelios, I., Gottwald, S., Rae, R., Lechner, S., Bayer, C., Dekempe, Q., Osl, F., Carrié, N., Kassem, S., Lorenz, S., Christopeit, T., Carpy, A., Bujotzek, A., Bröske, A. M., …, & Umaña, P. (2025). Forimtamig, a novel GPRC5D-targeting T-cell bispecific antibody with a 2+1 format, for the treatment of multiple myeloma. Blood. https://doi.org/10.1182/blood.2024025987
Vancouver
Eckmann J, Fauti T, Biehl M, Zabaleta A, Blanco L, Lelios I, et al. Forimtamig, a novel GPRC5D-targeting T-cell bispecific antibody with a 2+1 format, for the treatment of multiple myeloma. Blood. 2025. doi:10.1182/blood.2024025987
BibTeX
@article{Eckmann2025,
author = {Eckmann, Jan and Fauti, Tanja and Biehl, Marlene and Zabaleta, Aintzane and Blanco, Laura and Lelios, Iva and Gottwald, Stefan and Rae, Richard and Lechner, Stefanie and Bayer, Christa and Dekempe, Quincy and Osl, Franz and Carrié, Nadege and Kassem, Sahar and Lorenz, Stefan and Christopeit, Tony and Carpy, Alejandro and Bujotzek, Alexander and Bröske, Ann-Marie and Dekhtiarenko, Iryna and Attig, Jan and Kunz, Leo and Cremasco, Floriana and Adelfio, Roberto and Fertig, Georg and Dengl, Stefan and Gassner, Christian and Bormann, Felix and Kirstenpfad, Claudia and Kraft, Thomas and Diggelmann, Sarah and Knobloch, Melanie and Hage, Carina and Feddersen, Romi and Heidkamp, Gordon and Pöschinger, Thomas and Mayoux, Maud and Bernasconi, Luise and Prosper, Felipe and Dumontet, Charles and Martinet, Ludovic and Leclair, Stéphane and Xu, Wei and Paiva, Bruno and Klein, Christian and Umaña, Pablo},
title = {Forimtamig, a novel GPRC5D-targeting T-cell bispecific antibody with a 2+1 format, for the treatment of multiple myeloma},
journal = {Blood},
year = {2025},
doi = {10.1182/blood.2024025987}
}
EUVIMED